Regeneron Pharmaceuticals Inc. buy Barclays PLC
Start price
07.08.23
/
50%
€705.50
Target price
07.08.24
€817.83
Performance (%)
23.91%
Price
08:19
€874.20
Summary
This prediction is currently active. The prediction currently has a performance of 23.91%. This prediction currently runs until 07.08.24. The prediction end date can be changed by Barclays_PLC at any time. Barclays_PLC has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Regeneron Pharmaceuticals Inc. | 5.324% | 5.324% |
| iShares Core DAX® | 0.000% | -2.064% |
| iShares Nasdaq 100 | 0.626% | -2.884% |
| iShares Nikkei 225® | 1.568% | -5.892% |
| iShares S&P 500 | 0.334% | -2.281% |
Comments by Barclays_PLC for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target raised by analysts at Barclays PLC from $888.00 to $900.00. They now have an "overweight" rating on the stock.
Ratings data for REGN provided by MarketBeat
Stopped prediction by Barclays_PLC for Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€873.50
23.01.24
23.01.24
€938.09
23.01.25
23.01.25
0.08%
08:19
08:19
